B7-H3-Targeted Immunotherapy Candidates Pipeline Review
B7-H3-Targeted Immunotherapy Candidates Pipeline Review
Target: B7 homolog 3 protein; B7-H3; CD276
Product Category: Antibody; Cells
This product provides basic information on immunotherapy candidates in research and development targeting B7-H3.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapy candidates targeting B7-H3 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in a wide range of cancer types, including lung, prostate and esophageal, and its overexpression has been shown to correlate with poor prognosis in some cancers, making B7-H3 a promising therapeutic target. At the same time, B7-H3 is expressed at a low level in normal tissues. In malignant tissues, B7-H3 inhibits tumor antigen-specific immune responses, resulting in a protumorigenic effect. Additionally, B7-H3 promotes migration and invasion, angiogenesis, chemotherapy resistance, endothelial-to-mesenchymal transition, and affects tumor cell metabolism.
There are no B7-H3 directed medicines approved for the treatment of any cancer, but a number of effector-enhanced B7-H3-targeted immunotherapy candidates in preclinical and clinical development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models.